BioNexus Gene Lab (BGLC) Income from Continuing Operations (2018 - 2026)

BioNexus Gene Lab has disclosed Income from Continuing Operations across 9 years of filings, most recently posting 543575.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 543575.0, up 12.79% year-over-year; the trailing twelve-month figure through Mar 2026 was 2904855.0 (down 38.42% YoY), and the FY2025 annual result was 2984607.0, down 89.01% from the prior year.
• Income from Continuing Operations came in at 543575.0 for Q1 2026 at BioNexus Gene Lab, up from 1036117.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 351515.0 in Q4 2023 to a low of 2609189.0 in Q3 2023.
• The 5-year median for Income from Continuing Operations is 291231.0 (2023), against an average of 464966.59.
• Peak annual rise in Income from Continuing Operations reached 771.48% in 2023, while the deepest fall reached 3271.0% in 2023.
• BioNexus Gene Lab's Income from Continuing Operations stood at 52349.0 in 2022, then surged by 771.48% to 351515.0 in 2023, then sank by 193.6% to 329026.0 in 2024, then slumped by 214.9% to 1036117.0 in 2025, then surged by 47.54% to 543575.0 in 2026.
• The last three Income from Continuing Operations figures came in at 543575.0 (Q1 2026), 1036117.0 (Q4 2025), and 708991.0 (Q3 2025), per Business Quant data.